Jonathan A Kelber received his BS/MS in chemistry from Cal Poly Pomona. He received a PhD in biochemistry from UCSD. He completed an NIH-IRACDA postdoctoral fellowship with Richard Klemke at UCSD and identified the PEAK1 pseudokinase as a driver of cancer progression. He is an associate professor of biology at Baylor University and directs the NIH-funded Developmental Oncogene Laboratory. He was a 2013 ASBMB grant-writing scholar, a 2014 ASCB-MAC FRED program participant, a 2017 ASCB-MAC visiting professor with Joan Brugge's group at the Harvard Medical School Ludwig Center, the 2019/20 US-UK Fulbright-CRUK fellow with Martin Humphries' group at the University of Manchester, and the 2021 CSUPERB Faculty Research Award recipient. He serves as a member of the ASCB MAC and a member of the NIH Tumor Evolution Heterogeneity and Metastasis (TEHM) study section.
Jonathan A Kelber received his BS/MS in chemistry from Cal Poly Pomona. He received a PhD in biochemistry from UCSD. He completed an NIH-IRACDA postdoctoral fellowship with Richard Klemke at UCSD and identified the PEAK1 pseudokinase as a driver of cancer progression. He is an associate professor of biology at Baylor University and directs the NIH-funded Developmental Oncogene Laboratory. He was a 2013 ASBMB grant-writing scholar, a 2014 ASCB-MAC FRED program participant, a 2017 ASCB-MAC visiting professor with Joan Brugge's group at the Harvard Medical School Ludwig Center, the 2019/20 US-UK Fulbright-CRUK fellow with Martin Humphries' group at the University of Manchester, and the 2021 CSUPERB Faculty Research Award recipient. He serves as a member of the ASCB MAC and a member of the NIH Tumor Evolution Heterogeneity and Metastasis (TEHM) study section.